Board of Directors
Maurizio Chiriva-Internati, PhD
Maurizio Chiriva-Internati, PhD, D BSc, is Kiromic’s Chief Executive Officer and Chief Scientific Officer. For the past 20 years, Dr. Chiriva-Internati has investigated tumor antigens as therapeutic and diagnostic tools. His research has led to the identification of novel cancer testis antigens for the development of immunotherapeutic strategies against solid and non-solid tumors. Dr. Chiriva-Internati’s research is focused on developing new therapies for a variety of tumors, including multiple myeloma, acute myeloid leukemia, ovarian, lung, prostate, melanoma, and breast cancer. He is the author of 149 peer-reviewed publications, and is a journal reviewer for The Lancet Infectious Diseases, Cancer Research, The Journal of Immunology, International Reviews of Immunology, and Nature Reviews Clinical Oncology.
Gianluca Rotino is Kiromic’s Chief Strategy Officer and Head of Corporate Development. Mr. Rotino is a seasoned business executive with experience in corporate strategy, business development, and capital fund raising. In addition to working for Kiromic, Mr. Rotino holds positions as both CEO and Chairman of the Board for several Italian companies. His previous experience includes senior level managerial positions for companies in Italy in different fields, such as High Tech, International Development and Corporate Consulting. Mr. Rotino worked as a practitioner of international law in Milan, Italy, where he specialized in mergers, acquisitions, intellectual property, and corporate law.
Jason Terrell, MD, has extensive expertise in the pharmaceutical and medical diagnostic device industry in the areas of business development, clinical trial organization, regulatory affairs and commercialization strategies. Experience includes service as Chief Scientific Officer and Chief Medical Officer at Generex Biotechnology Corporation since January 18, 2017, Chief Executive Officer of Volition America Inc. since May 9, 2017, and Chief Medical Officer of VolitionRx Limited since January 1, 2016.
Scott Dahlbeck, MD, PharmD
Scott Dahlbeck, MD, PharmD, is Founder, President and Chief Operating Officer of Kiromic. Dr. Dahlbeck is an expert in prostate cancer research having served as a Radiation Oncologist of several cancer centers. Dr. Dahlbeck has also patented, manufactured, and commercialized intellectual property and has more than a decade of experience in medical and oncology commerce.
Peter is currently President & Chief Executive Officer and a member of the Board of Directors of TapImmune (Nasdaq: TPIV) a clinical-stage immuno-oncology company with ongoing clinical trials at the Mayo Clinic and Memorial Sloan-Kettering Cancer Center. Prior to TapImmune, he served as the Senior Vice President of Business Development & Strategy at Bellicum Pharmaceuticals (Nasdaq: BLCM), a clinical stage immuno-oncology and cell therapy company developing small molecule-controllable gene-modified T cell-based therapeutics. Previously, Peter led the new venture formation and development effort as the Managing Director, Innovations in the Strategic Industry Ventures department for The University of Texas MD Anderson Cancer Center. In addition to his executive management experience leading publicly traded biotechnology companies, Peter has over 18 years of finance and deal-making experience in investment banking and venture capital, advising on over 100 transactions with an aggregate deal value of over $120 billion. Prior to MD Anderson, Peter was a senior investment banker, most recently as Managing Director and head of global healthcare mergers & acquisitions advisory for CIT Group (NYSE: CIT). He has also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch and Deutsche Bank.